| Name | Tioxolone |
| Description | Tioxolone is a metalloenzyme carbonic anhydrase I inhibitor. |
| In vitro | Tioxolone, along with its Benzoxathiol derivatives, exhibits antibacterial and antifungal properties, as well as inhibitory effects on cell proliferation. These compounds have been utilized in topical treatments for common psoriasis and acne. |
| In vivo | Tioxolone exhibits sebum-regulating and antibacterial properties, thus it is incorporated in various cosmetics such as shampoos and skin cleansers. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 32 mg/mL (190.28 mM), Sonication is recommended. H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 45 mg/mL (267.59 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (11.89 mM), Sonication is recommended.
|
| Keywords | Tioxolone | Inhibitor | inhibit | CarbonicAnhydrase | Carbonic anhydrase I | Carbonic Anhydrase | Carbonate dehydratase |
| Inhibitors Related | Aceglutamide | Cysteamine hydrochloride | Sodium Dihydrogen Phosphate | Hydroxychloroquine | Metronidazole | 2-Amino-2-methyl-1-propanol | Doxycycline | Tributyrin | Fenpyroximate | Paeonol | Alginic acid | Dextran sulfate sodium salt (MW 5000) |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Glycometabolism Compound Library | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Approved Drug Library | ReFRAME Related Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library | Metabolism Compound Library | Cosmetic Ingredient Compound Library | Bioactive Compounds Library Max |